- \n
- What is personalized medicine?<\/a><\/li>\n
- The role of genetic testing in treatment<\/a><\/li>\n
- Precision medicine and the future of therapy<\/a><\/li>\n
- Deciphering genetic mysteries<\/a><\/li>\n
- Examples of precision therapy applications<\/a><\/li>\n
- The potential of stratified medicine<\/a><\/li>\n<\/ul>\n
What is personalized medicine?<\/h2>\n
Personalized medicine, often also called precision medicine, is an approach to diagnostics and treatment in which the patient ceases to be an “average case” and becomes a reference point in themselves. Instead of applying standard therapy protocols based solely on general guidelines, doctors analyze individual body characteristics\u2014primarily the genetic profile, but also lifestyle, environment, age, sex, coexisting diseases, or responses to previous therapies. As a result, the diagnostic-therapeutic process is “tailor-made”: it identifies the specific molecular causes of a disease in a given individual, predicts likely responses to various treatment methods, and selects the strategy with the greatest chance of success while minimizing the risk of adverse effects. In the classical medical model, a patient with a given diagnosis\u2014such as breast cancer or type 2 diabetes<\/a>\u2014receives treatment according to established protocols based on large population studies. However, this model assumes that most patients respond similarly, which in practice is often not the case: some respond very well, others not at all, and yet another group develops severe side effects. Personalized medicine is based on the notion that these differences have specific biological and genetic underpinnings, which can be identified using modern tools such as DNA sequencing, gene expression analysis, proteomic and metabolomic studies, as well as advanced data analysis systems. In practice, this means that two patients with the same diagnosis may receive completely different therapies\u2014because their disease, although labeled the same, has a different molecular basis and potential course. Pharmacogenomics, the field that studies how gene variants affect drug metabolism and effectiveness, plays a key role here. For example, some people have liver enzymes that work faster or slower due to genetic mutations, which may make a standard medication dose too high (risking toxicity) or too low (no therapeutic effect). Thanks to genetic testing, a physician can select the proper drug and dose even before starting treatment, reducing the \u201ctrial and error\u201d method and increasing treatment safety. Personalized medicine also includes prevention: knowing a person\u2019s individual genetic risk for cancer, cardiovascular disease, or neurological disorders allows targeted planning of screening tests, healthy diets, physical activity, and other interventions, rather than relying solely on general health recommendations for the entire population.<\/p>\n
However, personalized medicine is not just genetics in the narrow sense, but an entire ecosystem of patient data processed with advanced algorithms, including artificial intelligence<\/a> and machine learning. These models can analyze millions of variables\u2014from DNA sequences, laboratory and imaging tests, to data from activity and sleep monitoring devices\u2014to detect subtle patterns invisible to the human eye. As a result, it is possible to predict the risk of disease exacerbation, identify patients who will benefit most from a particular therapy, and even develop new drugs designed for specific molecular changes. In oncology, personalized medicine manifests, among other things, through so-called targeted therapies and immunotherapies selected based on the tumor profile, not just its location in the body. In cardiology, individual genetic predispositions to arrhythmias or thrombophilia are increasingly considered, affecting decisions on anticoagulant therapy or the type of implanted devices. In neurology, work is underway on biomarkers that can detect changes associated with Alzheimer\u2019s or Parkinson\u2019s disease at very early stages, when clinical symptoms are minimal and the chances for effective intervention are greatest. An essential element of the personalized medicine concept is the active role of the patient, who becomes a partner in the decision-making process. Having information about their risk profile, available diagnostic and therapeutic options, and their potential benefits and limitations, the patient can consciously co-decide on the chosen treatment path. Thus, personalization is not limited to matching a drug to a gene, but also includes values, preferences, and expectations of the individual. In this sense, personalized medicine combines hard scientific data with a holistic approach, integrating biological parameters with psychosocial context. Ultimately, its core is moving away from \u201cone standard for all\u201d in favor of a dynamic, data-based model of care, in which therapy is constantly adjusted in response to how the patient\u2019s body reacts and how their health evolves over time.<\/p>\n
The role of genetic testing in treatment<\/h2>\n
Genetic testing forms the foundation of personalized medicine because it provides information about the individual “instruction code” of the body, which largely determines disease development, drug response, and complication risks. Thanks to techniques like whole genome sequencing (WGS), whole exome sequencing (WES), and gene panels targeted to specific conditions, physicians can identify mutations, polymorphisms, and other genetic variants that directly impact therapy selection. In oncology, molecular profiling of a tumor is crucial, allowing the identification of specific gene changes (e.g., EGFR, ALK, BRAF, HER2) that are targets for molecularly targeted drugs. Instead of applying one treatment scheme to all patients with a type of cancer, it is now possible to tailor therapy to the tumor\u2019s “genetic signature,” increasing effectiveness, extending survival, and often avoiding toxic, wide-reaching chemotherapy. Genetic tests are also used to identify hereditary cancer syndromes, such as BRCA1\/2 mutations in breast and ovarian cancer or DNA repair gene mutations in colorectal cancer. This enables not only appropriate therapy selection (e.g., PARP inhibitors for BRCA mutation carriers), but also intensive prevention and screening programs for relatives who may carry the same mutations. In cardiology, genetic analyses help diagnose congenital cardiomyopathies, long QT syndromes, arrhythmogenic heart disease, and familial hypercholesterolemia, enabling treatment before a heart attack<\/a>, stroke, or sudden cardiac death occurs. A patient identified with a pathogenic mutation responsible for heart rhythm disorders may receive an implantable cardioverter-defibrillator, benefit from targeted pharmacotherapy, and undergo lifestyle modification, greatly reducing the risk of tragic complications. A similar approach is evolving in neurology, where genetic diagnostics of diseases such as muscular dystrophies, spinal muscular atrophy (SMA), and some forms of epilepsy open the door to gene therapies and novel drugs modulating gene expression. By discovering the cause of disease at the DNA level, treatment can be precisely selected, rather than merely alleviating symptoms.<\/p>\n
One particularly dynamic area is pharmacogenomics, which studies how genetic differences affect drug metabolism and efficacy. Variants in genes encoding cytochrome P450 enzymes (e.g., CYP2D6, CYP2C19, CYP3A4) determine whether someone is a so-called rapid, intermediate, or slow metabolizer of certain active substances. This impacts therapy efficacy and safety: a person with slow metabolism may experience strong side effects with a standard dose, while a rapid metabolizer receives too little drug to achieve a therapeutic effect. In clinical practice, genetic tests are increasingly performed prior to introducing antiplatelet drugs (e.g., clopidogrel), cytostatics, cancer drugs, and certain antidepressants and antiepileptics. The result allows the physician to choose the optimal preparation and dose before side effects occur, shortening the trial-and-error period and improving patient comfort. The role of genetic testing, however, goes beyond selection of specific medicinal substances\u2014it also includes predicting response to biological therapy<\/a> (e.g., TNF-alpha inhibitors in autoimmune diseases), assessing the risk of severe allergic reactions to drugs (e.g., HLA-B*57:01 and abacavir hypersensitivity), and identifying patients for whom therapy will be ineffective, thus sparing them unnecessary side effects and costs. Advanced genetic testing also enables therapy monitoring, for example through analysis of circulating tumor DNA (ctDNA) in the blood, which allows early detection of resistance and modification of the treatment plan before disease progression is visible on imaging studies. In more and more cases, genetic testing is thus becoming not a one-time test at the start of therapy, but part of continuous treatment oversight, supported by artificial intelligence algorithms analyzing huge collections of genomic, clinical, and environmental data.<\/p>\n
Precision medicine and the future of therapy<\/h2>\n
Precision medicine is changing the way we think about treatment\u2014from one-size-fits-all interventions to therapies designed like custom-made drugs. The development of whole-genome sequencing, transcriptomic, proteomic, and metabolomic profiling, combined with cloud data analysis and AI, allows the creation of precise “molecular fingerprints” of diseases. In oncology, this already translates into therapies targeting specific mutations (e.g., EGFR, ALK, BRAF, HER2), regardless of the tumor’s primary location. Increasingly, instead of saying “lung cancer” or “breast cancer,” experts use categories such as “cancer with mutation X,” reflecting the shift from an anatomical to a molecular classification. A similar paradigm is being adopted in autoimmune diseases (targeting specific cytokines and signaling pathways) and rare metabolic diseases, where mutation identification leads to the development of enzyme therapies or small molecules modulating specific protein activity. Within a few years, advanced diagnostics\u2014including so-called liquid biopsy detecting circulating tumor DNA\u2014may become standard tools for therapy monitoring and detecting recurrences at very early stages, even before changes are visible in imaging. Precision medicine also drives the development of biological and cellular therapies, such as CAR-T or therapies based on stem cell modification, where genetic profiling of both the patient and the disease is a prerequisite for treatment success. In cardiology, genetic panels are increasingly used to assess the risk of sudden cardiac death, cardiomyopathies, or genetically determined rhythm disorders, allowing, in practice, the implementation of prophylactic defibrillator implantation in individuals at high yet “invisible to the naked eye” risk. In diabetology and endocrinology, personalization manifests as matching drugs to the metabolic phenotype, including insulin secretion pattern or insulin sensitivity of tissues, and in the future\u2014in designing therapies regenerating pancreatic beta cells but only for selected patients with specific immunological and genetic backgrounds. Pharmacogenomics plays a key role\u2014it is increasingly integrated into electronic health record systems: algorithms can automatically alert the physician that a given drug, dose, or combination is not recommended for a particular patient due to genetic variants affecting metabolism (e.g., CYP2D6, CYP2C19, TPMT).<\/p>\n
\n![\"Personalized](\"https:\/\/najzdrowie.pl\/wp-content\/uploads\/Medycyna_spersonalizowana__Rewolucja_w_terapii_i_diagnostyce-1.webp\")
\n<\/a><\/p>\nThe future of therapy in precision medicine is not only about more accurate drugs, but above all, a new architecture of the entire healthcare system, with the patient\u2019s health data continuously analyzed at its center. \u201cDigital twin\u201d platforms are being developed\u2014computer models of a specific patient\u2019s body, based on their genome, test results, wearable device data, and treatment history. These models can simulate disease progression and predict how a patient would potentially respond to various therapeutic schemes before they are applied in reality. Artificial intelligence and machine learning will play a fundamental role in forecasting treatment effectiveness, identifying patients who will benefit most from costly targeted therapies, and detecting rare adverse events by analyzing massive datasets in real time. At the same time, personalized medicine paves the way for gene and genome editing therapies (e.g., CRISPR\/Cas9), which are already being tested under controlled clinical conditions in the treatment of some hereditary blood disorders, congenital muscular dystrophies, or inherited blindness. As costs decrease and the safety of such technologies improves, it will become possible not only to treat diseases but also to modify the risk of their occurrence in predisposed individuals\u2014bringing new ethical, legal, and social questions. Increasingly important will be risk stratification algorithms based on so-called polygenic risk scores, which, using many genetic variants, allow prediction of susceptibility to cardiovascular disease, type 2 diabetes, or certain cancers, and then help select preventive and therapeutic strategies maximizing clinical benefit. Another direction is the development of adaptive therapies, in which treatment is not set once and for all, but dynamically adjusted based on the body\u2019s biological response\u2014regular molecular studies, assessment of the tumor microenvironment, or changes in the gut microbiome. At the same time, issues relating to data protection, test standardization, economic accessibility, and training of medical staff must be addressed to ensure these advanced tools are used properly and beneficially. As precision medicine enters clinical practice, the role of the patient as an active participant in the therapeutic process\u2014co-deciding on therapy choice based on detailed information on potential benefits, risks, alternatives, as well as their own life preferences and values\u2014will increase, shifting the focus from disease-centered to fully human-centered care.<\/p>\n
Deciphering genetic mysteries<\/h2>\n
Personalized medicine is based on the assumption that in our DNA are encoded both predispositions to diseases and clues regarding the most effective therapeutic methods. Deciphering genetic mysteries involves gradually reading this code and translating it into clinical decision-making. The process begins with selecting the appropriate testing method: from classic single-gene tests to multigene panels to whole exome sequencing (WES) or whole genome sequencing (WGS). In oncology, this means, for example, molecular profiling of the tumor\u2014that is, analyzing tumor DNA for \u201cdriver\u201d mutations such as changes in EGFR, ALK, or BRAF genes. These become the targets for molecularly targeted therapies that block specific growth pathways responsible for tumor development. At the same time, germline (hereditary) studies evaluate genes such as BRCA1\/2, TP53, or DNA repair genes, allowing identification of people at high risk for tumors and implementing prophylactic actions: more frequent imaging, prophylactic surgeries, or early treatment with targeted drugs. Genome decoding, however, is about more than detecting single mutations; it involves analyzing networks of gene interactions, transcription regulators, microRNA, and epigenetic elements together shaping the image of disease in a given patient.<\/p>\n
A key challenge is distinguishing clinically relevant changes from biological “background,” that is, incidental variants with no effect on health. In everyone\u2019s DNA sequence are millions of differences compared to the reference genome, and the vast majority are neutral. That\u2019s why, after sequencing, advanced bioinformatic \u201cfiltering\u201d of data is necessary\u2014from raw nucleotide readings, through mapping to the reference genome, to identifying variants, classifying, and interpreting them. In clinical practice, variant databases (e.g., ClinVar, gnomAD), algorithms predicting pathogenicity (e.g., PolyPhen, SIFT), and guidelines from international societies (e.g., ACMG) are used to categorize variants as pathogenic, likely pathogenic, of unknown significance (VUS), likely benign, or benign. Modern AI-based tools learn from millions of clinical cases and \u201comics\u201d data (genomics, transcriptomics, proteomics) to increasingly accurately predict which combinations of genetic changes lead to particular clinical phenotypes. “Liquid biopsy” is also being used increasingly often\u2014analyzing circulating tumor DNA (ctDNA) in the blood instead of classic tissue biopsies. This allows dynamic tracking of tumor evolution, detection of molecular resistance to therapy, and real-time therapy adjustments. Deciphering genetic mysteries, however, involves more than DNA analysis alone; epigenetics also plays a role, studying chemical modifications that affect gene expression without changing nucleotide sequence. DNA methylation and chromatin profiling help explain why two people with a similar mutation may respond differently to therapy. Furthermore, integrating genetic data with information on lifestyle, environmental exposure, or gut microbiome enables ever more precise risk models and disease course predictions. This requires close cooperation between clinical geneticists, molecular biologists, bioinformaticians, and physicians of various specialties, along with careful genetic counseling to explain to patients the meaning, limitations, and potential family consequences of test results. In this sense, genome decoding is a continuous process\u2014interpretation of the same data may change over time as new scientific discoveries emerge, opening the door to updating recommendations for both therapy and prevention throughout the patient\u2019s life.<\/p>\n
Examples of precision therapy applications<\/h2>\n
Personalized medicine truly comes into its own where diseases have a clear molecular basis and classic treatment schemes prove insufficient. The most spectacular examples come from oncology, where genetic profiling of tumors has become standard in many cancer types. In breast cancer, identifying hormone receptors (ER, PR) and HER2 overexpression allows for targeted therapy selection\u2014from anti-estrogens to monoclonal antibodies that block HER2, such as trastuzumab. In lung cancer, testing for mutations in EGFR, ALK, ROS1, BRAF, or the presence of NTRK rearrangements enables the use of tyrosine kinase inhibitors which selectively block the growth signals of tumor cells. Thus, patients who previously had only toxic, limited-effect chemotherapy as an option can now receive targeted drugs<\/a>, often oral, allowing long-term disease control. Another example is colorectal cancer, where the presence of RAS or BRAF mutations determines if the patient will benefit from EGFR-targeted therapy, and in microsatellite instability-high (MSI-H) cancers, novel immune checkpoint inhibitors that unlock the immune response show particularly good results. Hemato-oncology is another flagship precision medicine field: in chronic myeloid leukemia, the identification of the BCR-ABL fusion gene led to the development of imatinib and subsequent tyrosine kinase inhibitors, transforming a fatal disease into a chronic one; in acute lymphoblastic leukemia with CD19 expression, personalized CAR-T immunotherapy is used\u2014patient lymphocytes are genetically modified to recognize and destroy cancer cells. Targeted and immunologic therapies are often selected based on broad NGS (Next Generation Sequencing) panels covering dozens or hundreds of genes, allowing the discovery of so-called “druggable mutations”\u2014even in rare tumors, such as NTRK-rearranged neoplasms, where the same kinase inhibitor is used regardless of the anatomic location. Liquid biopsy, which analyzes circulating tumor DNA from the blood, is increasingly used to monitor the effectiveness of targeted therapy, detect early recurrences, or the emergence of new resistance mutations, allowing therapy to be adjusted before clinical deterioration occurs.<\/p>\n
Beyond oncology, precision therapies are entering more and more branches of medicine, changing management of chronic and rare diseases. In cardiology, pharmacogenomics assists in selecting the right antiplatelet drug after a heart attack: in patients with specific CYP2C19 gene variants, clopidogrel is less well activated, so alternatives like prasugrel or ticagrelor are recommended. Similarly, in treating hypertension<\/a> or arrhythmias, genetic factors affecting metabolism of beta-blockers or ACE inhibitors are increasingly considered to avoid both ineffectiveness and serious side effects. Inherited arrhythmic syndromes, like long QT syndrome or hypertrophic cardiomyopathies, are identified with genetic panels, enabling tailored treatment strategies (from specific drugs to implantable cardioverter-defibrillator qualification), not only for the patient but for relatives as part of family prevention. In diabetology, genetic analyses make it possible to diagnose monogenic types of diabetes (MODY, neonatal), previously classified as type 1 or 2\u2014identifying a specific mutation may allow a switch from insulin therapy to oral hypoglycemics, greatly improving quality of life. In neurology, precision medicine is used for conditions such as spinal muscular atrophy (SMA), where drugs like nusinersen or gene therapies are selected and monitored based on SMN1 mutation type and SMN2 gene copy number; in epilepsy, identifying ion channel mutations assists in selecting drugs that will suppress rather than exacerbate seizures. For rare diseases, more patients now benefit from “reverse diagnostics,” broad exome or genome sequencing to first define the molecular cause and then consider possible therapies\u2014often in orphan drug programs. Pharmacogenomics is also used in psychiatry, where testing variants in genes like CYP2D6, CYP2C19, or SLC6A4 helps pick antidepressants and neuroleptics<\/a> with the best efficacy and tolerance profile for a specific patient. In autoimmune and rheumatologic diseases, choosing biological drugs (e.g., TNF-alpha, IL-6, JAK inhibitors) increasingly relies on molecular signatures and biomarker analysis from blood or joint fluid, allowing prediction of response and avoiding fruitless trials of multiple drugs. Complementing all these applications are digital tools\u2014apps monitoring vital signs, blood glucose, heart rhythm or physical activity\u2014feeding AI algorithms to create dynamic “risk profiles” and assist the physician in selecting proper interventions, from lifestyle changes to highly personalized pharmacotherapy.<\/p>\n
The potential of stratified medicine<\/h2>\n
Stratified medicine is an important intermediate stage between the traditional \u201cone-size-fits-all\u201d approach and fully personalized therapy. Its essence is dividing the patient population into relatively homogeneous subgroups\u2014strata\u2014based on common biological, genetic, clinical, or environmental features. Instead of creating a unique treatment plan for every individual, stratified medicine identifies groups likely to react similarly to a given therapy, better predicting effectiveness and safety. This greatly increases the chances of choosing the therapy with the highest benefit from the very first decision, while limiting costly and burdensome “trial and error” attempts at various treatment schemes. Key tools enabling stratification are biomarkers\u2014from simple lab parameters such as cholesterol level to complex molecular signatures covering combinations of genetic mutations, gene expression profiles, inflammatory markers, or metabolomic patterns. An example would be dividing cardiac patients based on specific gene variants affecting statin metabolism, allowing identification of those at higher risk for drug side effects and tailoring alternative therapy. In diabetology, the concept of differentiating diabetes types into finer clinical-molecular phenotypes is gaining traction, affecting therapy selection (e.g., distinguishing LADA from classic type 2 diabetes). Stratified medicine also utilizes imaging and signal data\u2014detailed MRI or CT analyses aided by artificial intelligence identify subgroups of neurology or brain tumor patients with different prognoses or responses to therapy despite similar clinical presentations. On a healthcare system level, stratification introduces a new level of population management. It enables segmentation of risk across whole populations, allowing payers and policymakers to direct resources where they have the greatest impact\u2014e.g., more intensive surveillance and preventive programs for patients at high cardiovascular risk defined by not only traditional indicators (age, smoking, hypertension), but also polygenic profiles, vascular imaging, or inflammatory markers. At the same time, stratified medicine can lead to better allocation of advanced, costly therapies such as immunotherapies or biological drugs, only to patients most likely to benefit. This opens the door to \u201cpay for performance\u201d reimbursement models, where the payer covers therapy costs if the patient is in a clearly defined stratum and achieves specified clinical results. Companion diagnostics are gaining importance as required elements of treatment qualification\u2014without a test result identifying the right stratum, the drug is not administered, which limits unnecessary costs and the risk of adverse events. In the development of clinical trials, stratified medicine enables adaptive and platform studies in which many patients with common molecular features are randomized to various therapies in one integrated protocol. Such studies increase the chances of quickly identifying effective therapy options for specific strata, while reducing the number of patients exposed to ineffective treatments. This, however, requires extensive data infrastructures, biomarker panel standardization, and close cooperation between research centers, the pharmaceutical industry, and regulatory agencies.<\/p>\n
- The role of genetic testing in treatment<\/a><\/li>\n